Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Search results for:

siltuximab

siltuximab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Sylvant POWDER FOR INJECTION, INTRAVENOUS 100 mg, 400 mg      
Comments:

Classified as formulary restricted, for use as approved under COVID-19 Drug Protocol for Adults, if tocilizumab and sarilumab cannot be used or are not available.

Restricted to ID physicians for the management of COVID-19.

 

Sylvant is non-formulary for other indications but may given via patient assistance program (PAP)/patient own medication if use is required.

If an Oncology provider orders this agent for treatment of Castleman disease, please contact Oncology Team.

Reviewed: 26 May 2015 (Sylvant), 28 April 2020 (COVID-19)

Last updated: Feb. 17, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved